Abilify, Risperdal Compete To Become First Antipsychotic Approved For Pediatric Schizophrenia
This article was originally published in The Pink Sheet Daily
Executive Summary
User fee date could be as early as June 21 for Johnson and Johnson subsidiary Janssen’s Risperdal, firm tells “The Pink Sheet” DAILY.